Business Wire

Starcity Acquires Ollie, Accelerating Its Growth as a Vertically Integrated Global Coliving Company

Share

Starcity is acquiring Ollie’s key assets, including its technology, intellectual property, and business agreements in major cities, which when combined with Starcity, will create one of the largest coliving developers and operators globally.

Ollie is widely recognized as a pioneer in the coliving asset class and has partnered with institutional owners to deliver much needed affordability and community to top tier cities such as New York, Los Angeles, the San Francisco Bay Area, and Boston. Additionally, Ollie has built a proprietary technology suite of services to foster community engagement, deliver hospitality services and provide roommate matching within its communities.

Following the transaction, Ollie’s key personnel will join Starcity to create a leading organization with the mission to make great cities accessible to everyone. “We are thrilled to bring on board such a high caliber team with institutional grade communities. Most importantly, we are humbled to expand our inviting, hands-on experience for more residents globally,” said Jon Dishotsky, CEO and co-founder of Starcity. Starcity will spend the coming months integrating the Ollie team, residents, and partners onto its platform. With the acquisition, Starcity will now operate over 1,500 units globally, with over 3,000 units in its development and operations pipeline throughout North America and Western Europe and over 10,000 units in negotiations.

Starcity has been expanding its footprint in the coliving industry with a focus on major cities in North America and Europe. With this acquisition, Starcity further establishes itself as a best-in-class owner and operator in institutional coliving with a full suite of services.

“Bringing the Ollie platform into Starcity gives our residents, clients, and team a company that is aligned on our housing philosophy, facilitating further growth of attainable housing nationally and globally,” said Gregg Christiansen, Ollie’s President. “I am excited to see what we can accomplish together.”

Contact information

Jon Dishotsky
Media@starcity.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EG Group Selects PDI to Bring Contactless Payments to its North American Sites18.1.2021 13:00:00 CETPress release

PDI (www.pdisoftware.com), a global provider of enterprise software solutions to convenience retailers and petroleum wholesalers, announced it has reached an agreement with EG Group to expand the use of PDI Payments to nearly 1,700 sites across North America. PDI added payments capabilities to its Marketing Cloud Solutions offering last year after acquiring ZipLine, the industry leader for ACH payment and provider of mobile payment technology. The PDI Payments platform currently powers EG Group’s SmartPay Rewards. The rewards program originated with Cumberland Farms—one of several U.S.-based convenience store brands EG Group acquired in recent years—and will soon be rolled out to EG Group’s remaining stores across North America. Customers can download the free app and enjoy a contactless payment experience, whether making purchases in the store or at the pump. PDI will provide the technology to support customer enrollment in SmartPay and deliver ongoing customer service for reward memb

Argo Blockchain PLC announces £22.4 Million Private Placement with Institutional Investors and Mining Capacity Expansion18.1.2021 09:46:00 CETPress release

Argo, the leading cryptocurrency miner based in the UK (LSE:ARB), is pleased to announce that it has entered into a securities purchase agreement for a private placement of its ordinary shares ("Ordinary Shares") to certain institutional investors for gross proceeds of GBP £22.4 million (the "Private Placement"). Pursuant to the Private Placement, the Company will issue 28 million Ordinary Shares (the “Placement Shares”) at a purchase price of GBP £0.80 per Ordinary Share. The Private Placement is limited to those certain institutional investors that have already subscribed and this announcement should not be considered an offer or solicitation to purchase or subscribe for securities in the United States. H.C. Wainwright & Co. is acting as the exclusive placement agent for the Private Placement. The net proceeds of the Private Placement will be used by the Company for working capital and general corporate purposes, including the expansion of the Company’s mining capacity in Q1 and Q2 o

Reply Signs an Agreement with AWS to Develop Industry Solutions18.1.2021 09:30:00 CETPress release

Reply, specialized on new communications channels and digital media, announces today it has signed a Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS) to develop industry solutions for Financial Services, Manufacturing, Automotive, Retail, Energy, and Telco customers. Through this SCA, the Reply Group of companies dedicated to AWS – Comsysto Reply, Data Reply, Sense Reply, and Storm Reply – will work with organizations of virtually all sizes and allow them to innovate faster and deliver consistent improvements on their business processes using advanced and secure AWS technologies. Reply’s companies dedicated to AWS will offer solutions for highly regulated Financial Services customers, providing them with strategic advisory and security-related consultancy, practices, and frameworks to modernize legacy platforms and solutions designed to address fraud and financial-crime use cases. They will also provide Industrial and Manufacturing customers with the tools they ne

L&T Technology Services Rated as Global Pure-Play ER&D Services Leader by Zinnov18.1.2021 09:00:00 CETPress release

L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global pure-play engineering services company, today announced that it has been rated as a ‘Leader’ in new technologies critical for products and services transformation and also placed in the Leadership Zone across major ER&D Services’ sectors in the Zinnov Zones 2020 ER&D Services study for the fourth consecutive year. LTTS continued to hold the top leadership position in the pure play ER&D Services category in the Zinnov Zones assessments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210118005070/en/ LTTS rated as a Global Leader in ER&D Services in Zinnov Zones 2020. (Graphic: Zinnov) In its latest industry rankings, Zinnov positioned L&T Technology Services as an “Expansive and Established” engineering partner with deep domain competencies in overall ER&D services. LTTS has been rated in the “Leadership Zone” across verticals such as Automotive, Aeros

Guardant Health and Vall d’Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in Europe18.1.2021 09:00:00 CETPress release

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading cancer research organizations, have agreed to enter into a partnership to establish in-house liquid biopsy testing services, using Guardant Health’s industry-leading proprietary digital sequencing platform, at VHIO’s facility in Barcelona, Spain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210118005057/en/ The service is expected to become operational in 2021 and will be available for clinical research and clinical care — starting with private patients, followed by expansion into the public healthcare system over time. “We are pleased to announce this partnership with VHIO which will bring liquid biopsy comprehensive genomic testing to more cancer patients in Spain and beyond,” said Helmy Eltoukhy, Guardant Health CEO. “Our vision is that all cancer patients globally have access

Topcon Announces eyeRISE 2021 Virtual Symposia & Expo18.1.2021 07:00:00 CETPress release

Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, announced today that it will host a two-day virtual symposia and expo entitled eyeRISE on February 9-10, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210117005025/en/ eyeRISE, or Eye Research Innovation Symposia & Expo, is a new, multi-disciplinary virtual congress showcasing the latest innovations in eye care. It will feature three solutions-focused tracks, delivering clinical and practical education through symposia, roundtable discussions and interactive workshops. (Graphic: Business Wire) eyeRISE, or Eye Research Innovation Symposia & Expo, is a new, multi-disciplinary virtual congress showcasing the latest innovations in eye care. It will feature three solutions-focused tracks, delivering clinical and practical education through symposia, roundtable discussions and interactive workshops. The two-day

Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF ® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy16.1.2021 22:15:00 CETPress release

Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine + bevacizumab (C-B) in a first-line setting for patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy.1 The data were announced today during an oral presentation at the 2021 ASCO Gastrointestinal Cancers Symposium (ASCO-GI). Patients with mCRC who are not eligible for chemotherapy face a large unmet need, with fewer treatment options available to them and lower survival rates. Colorectal cancer (CRC) makes up 9.7% of total global cancer cases, with almost 1.4 million new cases of CRC each year.2 In Europe, CRC is the second most common cause of death due to cancer, and those with a metastatic disease have a 5-year survival rate of just 11%.3 “For patients with metastatic colorectal cancer, those non-eligible for standard combination therapy have few options left and we are conti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom